ArticleJournal of experimental & clinical cancer research : CR2024

Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia.

Jun Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.